Stock 002693 HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Equities

002693

CNE100001K63

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.04 CNY +0.40% Intraday chart for Hainan Shuangcheng Pharmaceuticals Co., Ltd. +5.44% -32.89%
Mar. 18 Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules MT
Mar. 15 Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules
MT
Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia
MT
Shuangcheng Pharma Unit Passes US FDA On-Site Inspection
MT
Shuangcheng Pharma Shuangcheng Pharmaceutical Secures Pakistan Approval for Hepatitis, Tumor Drug
MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shuangcheng Pharma Flags 20 Million Yuan of Unrecovered Financial Products
MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shuangcheng Pharma Receives Nod to Produce Aseptic Products in Saudi Arabia
MT
Shuangcheng Pharmaceutical Gets Drug Production License
MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shuangcheng Pharma Applies to Have Stomach Drug Added to China’s Drug Procurement Scheme
MT
Hainan Shuangcheng Pharmaceutical Finalizes Transfer of Drug Rights
MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments
CI
Hainan Shuangcheng Pharmaceuticals Sells Injection Product Rights for 32 Million Yuan
MT
Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.
CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hainan Shuangcheng Subsidiary Agrees to Paclitaxel Production
MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002693 Stock
  4. News Hainan Shuangcheng Pharmaceuticals Co., Ltd.